Gleiss Lutz focuses on advising health insurance companies on patients rights, social security, regulatory and medical law, while the team is also increasingly being instructed by medical technology and pharmaceutical companies. Other growth areas include healthcare compliance and transactions. Clients' representation, including mass proceedings, is another mainstay of the practice; here, the practice frequently advises on claims for damages in the context of vaccine-related injuries. This is complemented by expertise in the areas of medicinal cannabis, data protection and digitisation as well as procurement and patent law. The interdisciplinary team is jointly led by Reimar Buchner (statutory health insurance, hospital, pharmaceutical and physician law) and Martin Viciano Gofferje (transactions and joint ventures).
Testimonials
Collated independently by Legal 500 research team.
- 'Extremely competent and client-oriented approach at eye level.'
- 'Excellent law firm for the pharmaceutical industry and the healthcare sector in general.'
Key clients
- AOKen (Bundesverband, Landesverbände)
- Bundesministerium für Gesundheit
Work highlights
- Advising Curaleaf Holdings, Inc. on the acquisition of a 55% stake in Four 20 Pharma GmbH, a fully EU GMP and GDP licensed German manufacturer and wholesaler of medicinal cannabis.
- Advising EuC Management Pty. Ltd on the market entry of the telemedicine portal Eucalyptus, which specializes in obesity.